Berlin - Delayed Quote EUR

Microbot Medical Inc (CY9D.BE)

2.2700

+0.0340

+(1.52%)

At close: May 23 at 8:08:24 AM GMT+2

Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

The addition of a seasoned VP of Marketing compliments the recent hiring of the Company’s VP of Sales to establish its commercialization readiness infrastructure Positive data from the recently published pivotal study raises confidence that LIBERTY® will be well received in the market HINGHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the addition of two senior officers that ro

GlobeNewswire last month

MBOT
Is Microbot Medical Inc. (MBOT) the Best Rising Penny Stock to Buy According to Analysts?

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Microbot Medical Inc. (NASDAQ:MBOT) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]

Insider Monkey last month

MBOT

^RUT
Microbot posts pivotal surgical robot data; GE Healthcare hires Patient Care Solutions leader

Microbot reported positive data on its single-use endovascular robot. Elsewhere, GE Healthcare named a new business leader, and Puzzle Medical Devices raised $31 million.

MedTech Dive last month

MBOT
Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 3.3% and th

PREMIUM
MT Newswires last month

MBOT

NEOG

CELG-RT
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed

GlobeNewswire last month

MBOT
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second QuarterBRAINTREE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is providing this reminder that data from the Company’s ACCESS-PVI trial will be presented by Francois Cornelis, MD, PhD, FCIRSE, Memorial Sloan Kettering Cancer Center, Department of Radiology. This is the first ti

GlobeNewswire last month

MBOT
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year This Appointment Represents the Company’s First Commercial Hire as it Ramps Up Commercial Readiness in Anticipation of FDA Clearance during the Second Quarter of 2025 BRAINTREE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Pa

GlobeNewswire 2 months ago

MBOT
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation modelBRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical® and Corewell Health™ are

GlobeNewswire 2 months ago

MBOT
Microbot Medical Closes $13 Million Registered Direct Offering

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I pr

GlobeNewswire 3 months ago

MBOT
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series I preferred investment options. The short-

GlobeNewswire 3 months ago

MBOT
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting

Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular roboticsBRAINTREE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the acceptance of a late-breaking abstract that will be presented at the upcoming Society of Interventional Radiology (SIR) annual meeting, being held in Nashville, TN on March 29 - April 2, 2025. The data from th

GlobeNewswire 3 months ago

MBOT
Why Microbot Medical Inc. (MBOT) Is Skyrocketing So Far In 2025

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Microbot Medical Inc (NASDAQ:MBOT) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. […]

Insider Monkey 3 months ago

MBOT
Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support CommercializationBRAINTREE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Ms. Michal Ahuvia, to the newly created role of Director of Operations. In this role, Ms. Ahuvia will assume responsibility to ramp-up production and improve product

GlobeNewswire 3 months ago

MBOT
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices MarketBRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and reve

GlobeNewswire 4 months ago

MBOT
Microbot Medical Closes $8.6 Million Registered Direct Offering

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H pr

GlobeNewswire 4 months ago

MBOT
Microbot Medical prices 3.79M shares at $2.27 in registered direct offering

Microbot Medical (MBOT) has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common s

TipRanks 4 months ago

MBOT
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series H preferred investment options. The short-te

GlobeNewswire 4 months ago

MBOT
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility

HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-

GlobeNewswire 4 months ago

MBOT
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 4,000,002 shares of the Company’s common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series G preferred investment options. The short-te

GlobeNewswire 4 months ago

MBOT
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®

Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, concludes 2024 with the achievement of several key milestones, including the recent FDA 510(k) submission for FDA commercial approval of LIBERTY®, which the company believes will position the Company for continued success in 2025. “As we entered 2024, the Company had thr

GlobeNewswire 4 months ago

MBOT

Performance Overview

Return	CY9D.BE	S&P 500 (^GSPC)
YTD	+111.16%	-1.34%
1-Year	+131.75%	+10.16%
3-Year	-49.86%	+46.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Microbot Medical Inc (CY9D.BE)

Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers

Is Microbot Medical Inc. (MBOT) the Best Rising Penny Stock to Buy According to Analysts?

Microbot posts pivotal surgical robot data; GE Healthcare hires Patient Care Solutions leader

Sector Update: Health Care Stocks Gain Late Afternoon

Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

Microbot Medical Closes $13 Million Registered Direct Offering

Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting

Why Microbot Medical Inc. (MBOT) Is Skyrocketing So Far In 2025

Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®

Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

Microbot Medical Closes $8.6 Million Registered Direct Offering

Microbot Medical prices 3.79M shares at $2.27 in registered direct offering

Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility

Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®

Performance Overview